Browse drugs

…or inhibitors (TNF-i) use (OR 0.502, 95% CI 0.312 to 0.808) and tocilizumab use (OR 0.493, 95% CI 0.304 to 0.799) were associated with sarc…

…t otherwise specified (PTCL-NOS). The disease was refractory to brentuximab vedotin plus cyclophosphamide, doxorubicin and prednisone, SMILE and pr…

…onths. Most common medication exposure (ever) were MMF (58.5%), prednisone (44.5%), HCQ (34.7%), MTX (29.5%), IVIg (13.6%), and cyclophosp…

…nts on corticosteroid therapy at doses higher than 10 mg/day of prednisone(or equivalent),with active infections or malignancies,were excl…

…ed so was discontinued.Other medications tried were colchicine, hydroxychloroquine, IV-Ig, and cyclosporine, tocilizumab and abatacept with subopt…

…tremities (71% knees), and 1 facial lesion. Treatments included prednisone (76%), mycophenolate mofetil (64%), endothelin receptor antagon…

…in 4 (17.4%), 7 (28.0%) and 11 (40.7%) patients in the placebo, nerandomilast 9 mg and 18 mg BID groups, respectively. Rates of treatment dis…

…ials in early and established RA, which compared GCs at ≤7.5 mg prednisone equivalent/day with placebo or standard of care. All patients c…

… plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, he had achieved a complete metabolic response by positron-emis…

…ith refractory CS or probable CS treated with the JAK inhibitor tofacitinib at the University Hospital Zurich from 2020 to 2024. Treatment …

…ease with highly variable manifestations. New therapies such as belimumab appear to reduce cumulative organ damage and disease flares, im…

…s conducted including NDMM patients aged ≥80 years treated with daratumumab from its introduction until January 2025. Baseline variables in…